Direct-acting antiviral agents against HCV with or without peginterferon plus ribavirin result in higher eradication rates of HCV and shorter treatment duration. We examined which is better for predicting persistent virologic response, the assessment of serum HCV RNA at 12 or 24 weeks after the end of treatment for predicting sustained virologic response (SVR12 or SVR24, respectively) in patients treated by HCV NS3/4A protease inhibitors with peginterferon plus ribavirin. | Sustained virologic response at 24 weeks after the end of treatment is a better predictor for treatment outcome in real-world HCV-infected patients treated by HCV NS3/4A protease inhibitors with peginterferon plus ribavirin
